BALTIMORE, March 4, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has issued a research update on Rexahn Pharmaceuticals, Inc., (NYSE Amex:RNN), a clinical stage pharmaceutical company commercializing potential best-in-class oncology and CNS therapeutics.
Rexahn has three drugs currently in Phase II clinical trials and each of these treatments has huge market potential, including treatments for depression, erectile dysfunction, and pancreatic cancer. Rexahn's unique technology has already received validation via a commercialization agreement with, and equity investment by Teva Pharmaceutical, a top 20 global pharmaceutical firm.
In the Goldman Select Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will occur in the second quarter of 2010, serving as catalysts for the Company's shares.
"We believe that Q2 could be a turning point for Rexahn. During the quarter, we expect the release of full-study Phase IIa results for both Serdaxin® and Zoraxel™, the Company's depression and erectile dysfunction treatments and we forecast that both trial results will be very favorable. In addition, we expect that the Company will receive another milestone payment from Teva towards the end of the period. All of these events should serve as catalysts for the stock."
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces stock market research reports. The Firm produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm's internally generated stock ideas while the Opportunity product reflects sponsored research reports. While performance is tracked separately, the same coverage criteria are utilized in determining coverage of all stocks in both research formats.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap research nor its parent is a registered investment adviser or broker-dealer. To download our research or for more information, visit www.goldmanresearch.com.
About Rexahn Pharmaceuticals: Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN) is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS (Central Nervous System) disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin™, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. www.rexahn.com